SynthesisMedicine2014
Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis.
Synthesis in Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Prognostic value of the pre-treatment SUVmax ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Diagnostic and prognostic value of pretreatment PET/CT in extranodal natural killer/T-cell lymphoma: a retrospective multicenter study.Journal of cancer research and clinical oncology · 2023Article
- Multimodality imaging evaluation of primary testicular extranodal natural killer/T-cell lymphoma: two case reports.Frontiers in medicine · 2023Article
- Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?Frontiers in oncology · 2023Review
- Review
- Weakly supervised deep learning for determining the prognostic value ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma.Medicine · 2020Article
- PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma.Journal of cancer research and clinical oncology · 2019Article
- Prognostic implications of circulating Epstein-Barr virus DNA for extranodal natural killer/T-cell lymphoma, nasal type: a meta-analysis.Cancer management and research · 2018Article
- Concurrent Primary Gastric and Pulmonary Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review.Gastroenterology research · 2017Article
- Article
- Utility of baseline, interim and end-of-treatmentScientific reports · 2017Article
- Pulmonary Extranodal Natural Killer/T-Cell Lymphoma (Nasal Type): A Case Report and Radiological Image Review.Medicine · 2015Article
- Article
- T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes.Korean journal of radiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of 18F-fuorodexoyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in the staging of Hodgkin lymphoma (HL) and aggressive B-cell non-Hodgkin lymphomas (NHL) has been demonstrated extensively. Nevertheless, the role of PET/CT in the diagnosis, staging, prognosis, and treatment evaluation of natural killer (NK)/T-cell lymphoma remains indeterminate. To systematically review and meta-analyze the publications on the value of 18F-FDG-PET/CT in the diagnosis and staging of NK/T-cell lymphoma. Pubmed, Embase, Cochrane Library, and some other database were searched for initial studies (last updated on May 8th, 2014).The eligibility criteria were studies assessing the usefulness of PET/CT in the staging of NK/T-cell lymphoma, patients were diagnosed as NK/T-cell lymphoma through pathology, or clinical and imaging follow-up. Sensitivities and specificities of 18F-FDG-PET/CT in individual studies were assessed. The summary receiver operating characteristic curve (sROC) and the area under the curve (AUC) were calculated. The "Meta-Disc 1.4" software was used for data analysis. Eight studies, with a total of 135 NK/T-cell lymphoma patients, were included in this meta-analysis. In terms of the 6 studies with patient based data, the pooled sensitivity and specificity of PET/CT in the diagnosis of NK/T-cell lymphoma were 0.95 (95% CI: 0.89-0.98) and 0.40 (95% CI: 0.09-0.78), respectively. For lesion-based analysis, with 1546 lesions included, the pooled sensitivity and specificity of PET/CT in the staging of NK/T-cell lymphoma were 0.98 (95% CI: 0.96-0.99) and 0.99 (95% CI: 0.99-1.00), respectively. For the patient based data, the AUC and Q index were 0.8537 and 0.7847, respectively. For lesion based data, the AUC and Q index were 0.9959 and 0.9755, respectively. The results of this current meta-analysis indicated that PET/CT could be used as a valuable diagnostic and staging tool for NK/T-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.